[1]黄蕤.NIS基因转染肿瘤细胞介导131I治疗[J].国际放射医学核医学杂志,2001,25(5):204-209.
　HUANG Rui.Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):204-209.
点击复制

NIS基因转染肿瘤细胞介导131I治疗(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第5期
页码:
204-209
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy
作者:
黄蕤
610041 四川 成都, 四川大学华西医院核医学科
Author(s):
HUANG Rui
Department of Nuclear Medicine, the West China Hospital, Sichuan University, Sichuan Chengdu 610041, China
关键词:
钠/碘同向转运体; 基因转染; 放射性碘治疗
Keywords:
Na+/I- symporter; gene transfection; radioiodide therapy
分类号:
R817.5
摘要:
钠/碘同向转运体(NIS)是一种跨膜糖蛋白,具有主动运输碘的能力。NIS的异常与许多甲状腺疾病有关。将NIS基因转染到肿瘤细胞使其表达NIS并摄取131I已获成功,但131I在细胞或病灶内停留的时间很短,达不到治疗剂量,故延长131I的有效半衰期和提高NIS转染率是今后研究的方向。
Abstract:
Na+/I- symporter is a membrane glycoprotein that catalyzes the active accumulation of I-. The abnormality of NIS gene will lead to thyroid disease. We had succeeded in transfecting the Na+/I- symporter into tumors for radioiodide concentration. However, the effective half life is too short to acquire therapeutic dose. So we should research into prolonging the effective half-life and increased effective transfection.

参考文献/References:

[1] Sphitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary DNA from salivary gland, mammary gland, and gstfic mucosa[J]. J Clin Endocrinol Metab, 1998, 83:1746-1751.
[2] Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter[J], Nature, 1996, 379:458-460.
[3] Smanik PA, Ryu KY, Karl S, et al. Expression, Exon-Intron Organization, and Chromosome Mapping of the Human Sodium Iodide Symporter[J]. Endocrinology, 1997, 138:3555-3558.
[4] Levy O, Antonio D L, Christopher S, et al. N-linked glycosylation of the thyroid Na+/I- symporter (NIS)[J]. J Biol Chem, 1998, 273:22657-22663.
[5] Eskandari S, Donald DF, Dai G, et al. Thyroid Na+/I- symporter[J]. J Biol Chem, 1997, 272:27230-27238.
[6] Kogai T, Endo T, Saito T, et al. Regulation by thyroid-stimulating hormone of Sodium/Iodide symporter gene expression and protein levels in FRTL-5 cells[J].Endocrinology, 1997, 138:2227-2232.
[7] Koichi S, Atsumi M, Saito J, et al. Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the Sodium/Iodide symporter gene[J]. Endocrinology, 1999, 140:5422-5430.
[8] Pekaxy AE, Hershman JM, Hershman, et al. Tumor necrosis factor, cerarmde, transforming growth factor-β1 and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells[J]. Endocrinology, 1998, 139:703-712.
[9] Fujiwara H, Tatsumi K, Miki K, et al. Congenital hypothyroidism caused by a mutation in the Na+/I- symporter[J]. Nature Genet, 1997, 16:124-125.
[10] Morris JC, Bergert ER, Bryant WP. Binding of immunoglobulin G from patients with autoimmune thyroid disease to rat sodium-iodide symporter peptides:evidence for the iodide transporter as autoantigen[J].Thyroid, 1997, 4:527-534.
[11] Seissler J, Wagner S, Matthias S, et al. Low frequency of autoantibodies to the human Na+/I- symporter in patients with autoimmune thyroid disease[J]. J Clin Endocrinol, 2000, 85:4630-4634.
[12] Chin HS, Chin DKH, Morgenthaler NG, et al. Rarity of anti-Na+/I- symporter (NIS) antibody with iodide uptake inhibiting activity in autoimmune thyroid diseases (AITD)[J]. J Clin Endocrinol, 2000, 85:3937-3940.
[13] Saito T, Endo T, Kawaguchi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas[J]. J Clin Invest, 1998, 101:1296-1300.
[14] Nakamoto Y, Saga T, Misaki T, et al. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy[J]. J Nucl Med, 2000, 41:1898-1904.
[15] Shimura H, Haraguchi K, Miyazaki A, et al. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene[J]. Endocrinology, 1997, 138:4493-4496.
[16] Mandell RB, Mandell LZ, Charles J, et al. Radiosotope concentrator gene therapy using the sodium/iodide symporter gene[J]. Cancer Res, 1999, 59:661-668.
[17] Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy[J]. Cancer Res, 2000, 60:3484-3492.
[18] Cho JY, Xing S, Liu X, et al. Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene therapy[J]. Gene Ther, 2000, 7:740-749.
[19] Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid therapy[J]. N Engl J Med, 1983, 309:937-941.
[20] Koong S, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic well-differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84:912-916.
[21] Schmutzler C, Winzer R, Carrasco N, et al. Retinoic acid-a potential bifunctional therapeutic tool for treating thyroid carcinomas[J]. Exp Clin Endocrinol Diabetes. 1998, 106(Suppl 1):s3.

相似文献/References:

[1]张一帆,李彪.钠/碘同向转运体在甲状腺癌131I治疗中的应用[J].国际放射医学核医学杂志,2004,28(6):249.
　ZHANG Yi-fan,LI Biao.Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):249.
[2]葛素娟.甲状腺癌术后131I治疗[J].国际放射医学核医学杂志,2002,26(4):163.
　GE Su-juan.131I therapy of thyroid cancer after surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):163.
[3]柳卫,张满达,王铁生.钠/碘同向转运体[J].国际放射医学核医学杂志,2001,25(2):49.
　LIU Wei.The sodium/iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):49.
[4]陈立波.钠/碘同向转运体与放射性碘治疗[J].国际放射医学核医学杂志,2001,25(6):258.
　CHEN Li-bo.The sodium/iodide symporter and radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):258.
[5]罗全勇.基因转染诱导核素靶向治疗的实验研究[J].国际放射医学核医学杂志,2001,25(2):60.
　LUO Quan-yong.Inducement of radionuclides targeting therapy by gene transfection[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):60.

备注/Memo

备注/Memo:
收稿日期:2001/7/21。
基金项目:国家自然科学基金资助项目(30170281)
作者简介:黄蕤(1977-),女,四川泸州人,四川大学华西医院核医学科硕士研究生
更新日期/Last Update: 1900-01-01